Cargando…

Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib

Rearrangement of anaplastic lymphoma kinase (ALK) gene is detected in approximately 5% of non-small cell lung cancer (NSCLC) patients. Tyrosine kinase inhibitors targeting ALK have significantly improved the prognosis of these patients. However, most patients experienced disease progression within a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rijavec, Erika, Biello, Federica, Indini, Alice, Grossi, Francesco, Genova, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786362/ https://www.ncbi.nlm.nih.gov/pubmed/35082536 http://dx.doi.org/10.2147/CPAA.S284850

Ejemplares similares

Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2023)

Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice
por: Siaw, Joachim T., et al.
Publicado: (2016)

The Effect of a High‐Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
por: Tugnait, Meera, et al.
Publicado: (2018)

Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
por: Indini, Alice, et al.
Publicado: (2021)

Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase‐positive non‐small cell lung cancer
por: Gupta, Neeraj, et al.
Publicado: (2022)

Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review
por: Indini, Alice, et al.
Publicado: (2021)

Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
por: Indini, Alice, et al.
Publicado: (2021)

Novel treatment strategies for early-stage lung cancer: the oncologist’s perspective
por: Indini, Alice, et al.
Publicado: (2020)

Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study
por: Gupta, Neeraj, et al.
Publicado: (2020)

Coronavirus infection and immune system: An insight of COVID-19 in cancer patients
por: Indini, Alice, et al.
Publicado: (2020)

Corrigendum to: Brigatinib dose rationale in anaplastic lymphoma kinase–positive non‐small cell lung cancer: Exposure–response analyses of pivotal ALTA study
Publicado: (2021)

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China
por: Luo, Xia, et al.
Publicado: (2022)

Letter of response to comments on: Developing a risk assessment score for patients with cancer during COVID-19 pandemic: A war on two fronts
por: Indini, Alice, et al.
Publicado: (2020)

Developing a risk assessment score for patients with cancer during the coronavirus disease 2019 pandemic
por: Indini, Alice, et al.
Publicado: (2020)

P1166: BRIGATINIB IN PATIENTS WITH ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA WHO HAVE FAILED BRENTUXIMAB VEDOTIN
por: Veleanu, Layla, et al.
Publicado: (2023)

Synthesis and Preclinical Evaluation of [Methylpiperazine-(11)C]brigatinib as a PET Tracer Targeting Both Mutated Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase
por: Högnäsbacka, Antonia A., et al.
Publicado: (2023)

Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System
por: Truini, Anna, et al.
Publicado: (2014)

Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
por: Alama, Angela, et al.
Publicado: (2019)

Anaplastic lymphoma kinase aberrations correlate with metastatic features in pediatric rhabdomyosarcoma
por: Gasparini, Patrizia, et al.
Publicado: (2016)

Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
por: Tugnait, Meera, et al.
Publicado: (2019)

Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison
por: Yu, Yongfeng, et al.
Publicado: (2022)

Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis
por: Indini, Alice, et al.
Publicado: (2020)

Role and targeting of anaplastic lymphoma kinase in cancer
por: Della Corte, Carminia Maria, et al.
Publicado: (2018)

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial
por: Christopoulos, Petros, et al.
Publicado: (2021)

Primary gastric anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma
por: Tian, Chen, et al.
Publicado: (2016)

Leukemic manifestation of anaplastic lymphoma kinase-negative-type anaplastic large-cell lymphoma
por: Kim, Jae Wook, et al.
Publicado: (2012)

Anaplastic Lymphoma Kinase in Cutaneous Malignancies
por: Cao, Severine, et al.
Publicado: (2017)

Targeting anaplastic lymphoma kinase in neuroblastoma
por: Umapathy, Ganesh, et al.
Publicado: (2019)

Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature
por: Heregger, R., et al.
Publicado: (2021)

Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges
por: Rijavec, Erika, et al.
Publicado: (2019)

Anaplastic Lymphoma Kinase Immunocytochemistry in Fine Needle Aspiration Diagnosis of Anaplastic Large-cell Lymphoma
por: Ramteke, Prashant, et al.
Publicado: (2018)

An Exploration into the Origins and Pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-Positive
por: Turner, Suzanne D.
Publicado: (2017)

Anaplastic lymphoma kinase–positive anaplastic large cell lymphoma presenting as diffuse pulmonary infiltrates
por: Sato, Shuku, et al.
Publicado: (2020)

Anaplastic lymphoma kinase: signalling in development and disease
por: Palmer, Ruth H., et al.
Publicado: (2009)

The role of anaplastic lymphoma kinase in pediatric cancers
por: Takita, Junko
Publicado: (2017)

Anaplastic lymphoma kinase inhibitor-associated myositis
por: Uruha, Akinori, et al.
Publicado: (2020)

Anaplastic lymphoma kinase inhibitors and their effect on the kidney
por: Bonilla, Marco, et al.
Publicado: (2022)

Anaplastic lymphoma kinase-special immunity and immunotherapy
por: Guo, Ye, et al.
Publicado: (2022)

The Appropriateness of Invasive Ventilation in COVID-19 Positive Cancer Patients: Proposal of a New Prognostic Score
por: Ghidini, Michele, et al.
Publicado: (2021)

Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform
por: Vanni, Irene, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qlbl0gc6r9mra17evlla5v4gt6